The global organoids market is expected to grow from USD 2.50 billion in 2022 to USD 8.12 billion by 2028 at a CAGR of 21.8% from 2023 to 2028, according to the latest research study by The Insight Partners. Organoids are tiny, self-organized, three-dimensional tissue cultures derived from stem cells that replicate the complexity of an organ or express specific aspects of it. Key companies operating in the market include STEMCELL Technologies, Cellesce, Hubrecht Organoid Technology, Definigen, Organoid Therapeutics, PeproTech, Thermo Fisher Scientific, Corning, Merck, and InSphero. Product innovation strategies, such as developing iPSC-derived intestinal organoids, creating cutting-edge technology to work with patient-derived intestinal organoids, and integrating automation with cell culture systems, are among the recent developments in the market. The growing adoption of personalized medicine, which accounted for more than 25% of new FDA-approved molecular entities in 2016, is fueling the growth of the organoids market. Pharmacies’ proactive education and awareness creation of precision medicine also drive demand for personalized therapies. These advances provide exciting opportunities to improve patient care, particularly in personalized cancer therapy of gene-drug associations, treatment, identification of new therapies, and predicting patient outcomes.
Organoids Market to Reach $8.12 Billion by 2028 at 21.8% CAGR with Intestine Segment Driving Growth During 2023-2028
Date:
Updated: [falahcoin_post_modified_date]